A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356
Status:
Terminated
Trial end date:
2021-10-29
Target enrollment:
Participant gender:
Summary
This is a 2-part, single-centre, randomised study in healthy males. Part 1 is a double-blind,
randomised, placebo-controlled, single ascending dose (SAD) study in healthy males. Part 2 is
a double-blind, randomised, placebo-controlled, multiple ascending dose (MAD) study in
healthy males.